A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
← catalyst calendarNCT05164094 · readout in 46 d
Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
867actual
Sites
65
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-28 | actual | When the study began enrolling |
| Primary completion | 2026-10-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-18 | estimated | The whole study's end, after follow-up |
| First posted | 2021-12-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Epstein-Barr Virus Infection
Interventions
- Biological: mRNA-1189
- Biological: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
measured Up to Day 176 (7-day follow-up after vaccination)
Number of Participants with Unsolicited Adverse Events (AEs)
measured Up to Day 197 (28-day follow-up after vaccination)
Number of Participants with SAEs, MAAEs, Any AEs Leading to Withdrawal From Study/Discontinuation of Study Vaccine and AEs of Special Interest (AESIs)
measured Day 1 to end of study (EOS) (Day 505)
Number of Participants with Laboratory Abnormalities
measured Up to Day 176 (7-day follow-up after vaccination)
Publications
- PMID 38957951 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed